World Antibiotics Awareness Week focuses on the threat of antibiotic resistance to key...
World Antibiotic Awareness Week: tackling multi-drug resistant bacteria
World Antibiotics Awareness Week focuses on the threat of antibiotic resistance to key part. A key part of solving the AMR crisis is to develop novel therapies to tackle resistance, particularly targeting those bacteria that are resistant to multiple antibiotics. One innovative approach is leveraging biology to create phage-based therapies.
Beigene receives its first FDA approval for a MCL drug
Chinese-headquartered Beigene has announced the US Food and Drug Administration (FDA) has approved Brukinsa (zanubrutinib) to treat patients with relapsed or refractory mantle cell lymphoma (MCL), making this the first Beigene-discovered product to gain FDA approval.
Sarepta and StrideBio sign gene therapy development deal
Sarepta Therapeutics has partnered with StrideBio for the development of in-vivo adeno-associated viral (AAV) based therapies for up to eight targets of the central nervous system (CNS) and neuromuscular conditions.
Bayer to invest $100m for alliance with Dewpoint Therapeutics
Bayer has entered an option, research and licence agreement valued at approximately $100m with Dewpoint Therapeutics to develop therapies for cardiovascular and gynaecological conditions.
One step closer to a Chlamydia vaccine
Researchers from Danish SSI and Imperial College London have published promising results from the first clinical trials of a vaccine against chlamydia. This represents a significant step toward a preventative treatment for the world’s most common sexually transmitted bacterial disease. Allie Nawrat examines the history of chlamydia treatment and the next steps in the development of the vaccine.
US researchers launch neurohub for brain disease therapies
US researchers have launched a research network, Weill Neurohub, to develop treatments for brain and nervous system diseases and disorders.
Skyhawk and Celgene expand alliance to identify new drug targets
Skyhawk Therapeutics has formed a second alliance with an affiliate of Celgene to identify drug targets in autoimmune diseases, oncology and immuno-oncology.
Vaximm partners with NEC on neoantigen cancer vaccines
Biotech company Vaximm has partnered with technologies provider NEC Corporation to develop personalised neoantigen cancer vaccines.
Johns Hopkins researchers develop anti-cancer compound
Researchers at Johns Hopkins Medicine in the US have developed a compound to block glutamine metabolism, slowing tumour growth, altering the tumour microenvironment and boosting the anti-tumour T-cell generation.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.